We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diagnostics Company Provides Clinical Interpretation of Genomics Data

By LabMedica International staff writers
Posted on 30 Jan 2013
A diagnostics company was launched to provide rapid, accurate, and turnkey clinical interpretation of genomics data at the point-of-care (POC). More...
The next phase of genomics-based medicine will provide clinicians with the tools they need to make faster, more precise and cost-saving decisions.

SV Bio’s (Foster City, CA, USA) turnkey genomics interpretation services query the patient’s genome at the POC and provide the biologic data in a concise, actionable report that medical generalists and specialists can easily use as a decision support tool. The platform fits into current clinical workflows and is able to take data from any next generation sequencer and determine, with clinical grade sensitivity and specificity, which genetic variants within a patient’s DNA sequence are influencing a disease or condition.

Many patients have already been helped by SV Bio diagnostic services. One case involved a family with two affected children who were initially thought to have autism spectrum disorder due to their language regression, IQ drops, and seizures at two years of age. Subsequent neurodegenerative decline puzzled physicians at leading medical institutions, and triggered a multiyear odyssey of clinical workups and focused genetic testing. Ultimately, the physicians turned to SV Bio, where the patient genomes were sequenced and the underlying genetic mutation in a gene named TPP1 was uncovered immediately.

The gene defect causes the rare disease late-infantile neuronal ceroid lipofuscinosis that is fatal by 8 years of age. The mutation was verified biochemically to be causative of the disorder, and allowed the children to gain access to a clinical trial that has shown promising results at halting the progression of the disease—a trial to which they would never have turned for a solution to a fatal disease in the absence of a specific molecular diagnosis.

“The transition is occurring very rapidly nowadays from genomics as a science to genomics as a key driver of clinical medicine and decision-making at the bedside,” noted Dietrich Stephan, PhD, SV Bio founder and CEO.

SV Bio is currently providing diagnostic testing services to physicians and centers of excellence for all heritable genetic conditions. These services include testing single genes and bundled gene sets for disorders that are genetically heterogeneous and for which the causative genes are known. In addition, testing of the entire genome is available for mystery illnesses or in cases where other diagnostic companies could not return a definitive result because the causative gene is not known, or in cases where a variant was detected but could not be classified as causative. SV Bio uses classification technology that provides precision of pathogenicity prediction for variants not been seen before—increasing sensitivity when coupled with the highest quality next-generation
sequencing of the entire genome.

Related Links:
SV Bio


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.